| Literature DB >> 29285393 |
Ling Zhang1, Bing Long1, Xiao-Qing Li1, Zhi-Gang Fang1, Wen-Xing Lai1, Dong-Jun Lin1.
Abstract
Long-term utilization of immunosuppression in organ transplant recipients leads to decreased immune-mediated tumor surveillance and increased risk of developing malignant tumors. However, chronic myeloid leukemia (CML) following living donor liver transplantation (LDLT) is rarely reported. The current case report presents a 42-year-old male patient who developed CML 14 months following LDLT. The patient achieved complete hematologic remission and early molecular response at 3 months imatinib treatment and major molecular response at 12 months imatinib treatment. The pathogenesis, risk factors, treatment and prognosis for CML following liver transplantation are unclear. Therefore, further analysis through accumulation of cases will be of great importance to prevent and treat this rare complication following liver transplantation.Entities:
Keywords: chronic myeloid leukemia; immunosuppression; liver transplantation
Year: 2017 PMID: 29285393 PMCID: PMC5740856 DOI: 10.3892/mco.2017.1465
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450